Your browser doesn't support javascript.
loading
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
Hwang, Jessica P; Suarez-Almazor, Maria E; Cantor, Scott B; Barbo, Andrea; Lin, Heather Y; Ahmed, Sairah; Chavez-MacGregor, Mariana; Donato-Santana, Christian; Eng, Cathy; Ferrajoli, Alessandra; Fisch, Michael J; McLaughlin, Peter; Simon, George R; Rondon, Gabriela; Shpall, Elizabeth J; Lok, Anna S.
Afiliação
  • Hwang JP; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Suarez-Almazor ME; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cantor SB; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Barbo A; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lin HY; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ahmed S; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Chavez-MacGregor M; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Donato-Santana C; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Eng C; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fisch MJ; Medical Oncology, Aim Specialty Health, Deerfield, Illinois.
  • McLaughlin P; Physicians Network, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Simon GR; Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rondon G; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lok AS; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
Cancer ; 123(17): 3367-3376, 2017 Sep 01.
Article em En | MEDLINE | ID: mdl-28518219
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus da Hepatite B / Neoplasias Hematológicas / Hepatite B Crônica / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus da Hepatite B / Neoplasias Hematológicas / Hepatite B Crônica / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2017 Tipo de documento: Article